JAK2V617F mutation not necessary1

Because myelofibrosis is not mutation specific, no particular clonal marker—including JAK2V2617F—is necessary for the diagnosis.1

Myelofibrosis can be diagnosed in places or circumstances where genetic testing is not possible by applying the World Health Organization (WHO) criteria.1

Incidence of JAK2V617F mutation in myeloproliferative neoplasms (MPNs)2,3

myeloproliferative neoplasms

JAK=Janus kinase.

JAK2V617F mutation status neither predictive nor prognostic in myelofibrosis4

Regardless of the pathogenesis of a given myelofibrosis patient’s symptoms and splenomegaly, the JAK pathway is overactive.3,5,6

Knowing the exact reason for a particular patient’s overactive JAK pathway appears to have only limited practical value when it comes to the management of myelofibrosis.1,7

WHO diagnostic criteria for
diagnosing myelofibrosis1

What is the significance of the JAK2V617F mutation in myelofibrosis?

The JAK2V617F Mutation and Myeloproliferative Neoplasms


  1. Vardiman JW, Thiele J, Arber DA, et al. Blood. 2009;114:937-951.
  2. Vainchenker W, Constantinescu SN. Hematology. 2005:195-200.
  3. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. Blood. 2011;118:1723-1735.
  4. Cervantes F, Dupriez B, Pereira A, et al. Blood. 2009;113:2895-2901.
  5. Quintás-Cardama A, Vaddi K, Liu P, et al. Blood. 2010;115:3109-3117.
  6. Fourouclas N, Li J, Gilby DC, et al. Haematologica. 2008;93:1635-1644.
  7. Verstovsek S, Kantarjian H, Mesa RA, et al. N Engl J Med. 2010;363:1117-1127.